Intrathecal gabapentin to treat chronic intractable noncancer pain

Anesthesiology

Volumn 119, Issue 3, 2013, Pages 675-686

  Rauck, Richard ^a   Coffey, Robert J ^b   Schultz, David M ^c   Wallace, Mark S ^d   Webster, Lynn R ^e   McCarville, Sally E ^b   Grigsby, Eric J ^f   Page, Linda M ^b  

^a National Textiles LLC   (United States)

^b MEDTRONIC INC   (United States)

^c Medical Pain Clinics   (United States)

^d UCSD MEDICAL CENTER   (United States)

^e Lifetree Clinical Research and Pain Clinic   (United States)

^f Napa Pain Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PLACEBO; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CONTINUOUS INFUSION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; INTRACTABLE PAIN; INTRATHECAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE; CLINICAL TRIAL; INTRASPINAL DRUG ADMINISTRATION; MIDDLE AGED; PAIN, INTRACTABLE;

ADULT; AGED; AMINES; ANALGESICS; CHRONIC PAIN; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; INJECTIONS, SPINAL; MALE; MIDDLE AGED; PAIN, INTRACTABLE;

EID: 84883235844     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3182a10fbf     Document Type: Article

References (40)

1. Merskey H, Bogduk N: Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd edition. Seattle, IASP Press, 1994
2. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277-84
3. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM: Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60: 1524-34 (Pubitemid 37443116)
4. Wallace MS: Human spinal drug delivery: Methods and technology, Spinal Drug Delivery. Edited by Yaksh TL. Amsterdam, Netherlands, Elsevier, 1999, pp 345-70
5. Taylor JC, Brauer S, Espir ML: Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 1981; 57: 16-8 (Pubitemid 11141958)
6. Taylor CP: Mechanisms of action of gabapentin. Rev Neurol (Paris) 1997; 153(suppl 1):S39-45
7. Cheng JK, Pan HL, Eisenach JC: Antiallodynic effect of intrathecal gabapentin and its interaction with clonidine in a rat model of postoperative pain. Anesthesiology 2000; 92: 1126-31 (Pubitemid 30180990)
8. Cho HS, Kim MH, Choi DH, Lee JI, Gwak MS, Hahm TS: The effect of intrathecal gabapentin on mechanical and thermal hyperalgesia in neuropathic rats induced by spinal nerve ligation. J Korean Med Sci 2002; 17: 225-9
9. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271: 5768-76 (Pubitemid 26083915)
10. Hwang JH, Yaksh TL: Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Reg Anesth 1997; 22: 249-56 (Pubitemid 27217143)
11. Jun JH, Yaksh TL: The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg 1998; 86: 348-54 (Pubitemid 28079490)
12. Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK: Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther 2002; 302: 1168-75 (Pubitemid 34920240)
13. Lu Y, Westlund KN: Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats. J Pharmacol Exp Ther 1999; 290: 214-9 (Pubitemid 29302322)
14. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, Myers RR: Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 2002; 303: 1199-205 (Pubitemid 35424406)
15. Marais, E., Klugbauer N, Hofmann F: Calcium channel α(2)δ subunits-structure and gabapentin binding. Mol Pharmacol 2001; 59: 1243-8 (Pubitemid 32381604)
16. Partridge BJ, Chaplan SR, Sakamoto E, Yaksh TL: Characterization of the effects of gabapentin and 3-isobutylgamma- aminobutyric acid on substance P-induced thermal hyperalgesia. Anesthesiology 1998; 88: 196-5
17. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 233-49 (Pubitemid 28137601)
18. Yoon MH, Yaksh TL: The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. Anesth Analg 1999; 89: 434-9 (Pubitemid 29367730)
19. Yoshizumi M, Parker RA, Eisenach JC, Hayashida K: Gabapentin inhibits γ-amino butyric acid release in the locus coeruleus but not in the spinal dorsal horn after peripheral nerve injury in rats. Anesthesiology 2012; 116: 1347-53
20. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324-34 (Pubitemid 40411499)
21. Gordh TE, Jensen TS, Kalso E: Reporting of trials of cabapentin (Letter). N Engl J Med 2010; 362:1641
22. Raja SN, Haythornthwaite JA: Combination therapy for neuropathic pain-Which drugs, which combination, which patients? N Engl J Med 2005; 352: 1373-5 (Pubitemid 40411506)
23. Vedula SS, Bero L, Scherer RW, Dickersin K: Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009; 361: 1963-71
24. Vollmer KO, Anhut H, Thomann P, Wagner F, Jahncken D: Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. Adv Epileptology 1989; 17: 209-11
25. Bockbrader HN: Clinical pharmacokinetics of gabapentin. Drugs Today 1995; 31: 613-9 (Pubitemid 26048983)
26. Ben-Menachem E, Persson LI, Hedner T: Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. Epilepsy Res 1992; 11: 45-9
27. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 9-9
28. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN: Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000; 40: 123-7 (Pubitemid 30339403)
29. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN: A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993; 10: 276-81 (Pubitemid 23041744)
30. Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, Chappell A, Chartier K, Cleeland CS, Costello A, Cowan P, Dimitrova R, Ellenberg S, Farrar JT, French JA, Gilron I, Hertz S, Jadad AR, Jay GW, Kalliomäki J, Katz NP, Kerns RD, Manning DC, McDermott MP, McGrath PJ, Narayana A, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Reeve BB, Rhodes T, Sampaio C, Simpson DM, Stauffer JW, Stucki G, Tobias J, White RE, Witter J: Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010; 149: 177-93
31. Katz J, Finnerup NB, Dworkin RH: Clinical trial outcome in neuropathic pain: Relationship to study characteristics. Neurology 2008; 70: 263-72 (Pubitemid 351156805)
32. Fleiss JL: Analysis of data from multiclinic trials. Control Clin Trials 1986; 7: 267-75 (Pubitemid 17204882)
33. Hochberg Y, Benjamini Y: More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811-8 (Pubitemid 20343989)
34. Williams DA: A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 1971; 27: 103-17
35. Williams DA: The comparison of several dose levels with a zero dose control. Biometrics 1972; 28: 519-31
36. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71
37. Casarett D, Karlawish J, Sankar P, Hirschman K, Asch DA: Designing pain research from the patient's perspective: What trial end points are important to patients with chronic pain? Pain Med 2001; 2: 309-16 (Pubitemid 34092755)
38. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-38
39. Eisenach JC: Clinical implementation of agents for spinal delivery, Spinal Drug Delivery. Edited by Yaksh TL. Amsterdam, Netherlands, Elsevier, 1999, pp 439-56
40. Deer T, Krames ES, Hassenbusch SJ, Burton A, Caraway D, Dupen S, Eisenach J, Erdek M, Grigsby E, Kim P, Levy R, McDowell G, Mekhail N, Panchal S, Prager J, Rauck R, Saulino M, Sitzman T, Staats P, Stanton-Hicks M, Stearns L, Willis KD, Witt W, Follett K, Huntoon M, Liem L, Rathmell J, Wallace M, Buchser E, Cousins M, Ver Donck A: Polyanalgesic consensus conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel. Neuromodulation 2007; 10: 300-28 (Pubitemid 47481102)